Xin Wu1, Shiqin Li2, Dongjie Chen3, Guiping Zheng4, Zhaohua Zhang4, Zian Li5, Xiaoying Sun6, Qiangqiang Zhao4, Jingjuan Xu7. 1. Department of Spine Surgery, The Third Xiangya Hospital, Central South University Changsha 410013, Hunan, China. 2. Department of Cell Biology, School of Life Sciences, Central South University Changsha 410013, Hunan, China. 3. Department of Hepatopancreatobiliary Surgery, The Third Xiangya Hospital, Central South University Changsha 410013, Hunan, China. 4. Department of Hematology, The Qinghai Provincial People's Hospital Xining 810007, Qinghai, China. 5. Department of Clinical Laboratory, Qinghai Provincial People's Hospital Xining 810007, Qinghai, China. 6. Department of Emergency, The Qinghai Provincial People's Hospital Xining 810007, China. 7. Department of Outpatient, The First People's Hospital of Changzhou Changzhou 213000, Jiangsu, China.
Abstract
OBJECTIVE: To determine the prognostic significance of inflammatory response-associated genes in acute myeloid leukemia (AML). METHODS: Transcriptomic profiles and related clinical information of AML patients were acquired from a public database. To establish a multi-gene prognosis signature, we performed least absolute shrinkage and selection operator Cox analysis for the TCGA cohort and evaluated the ICGC cohort for verification. Subsequently, Kaplan-Meier analysis was carried out to compare the overall survival (OS) rates between high- and low-risk groups. Biological function and single-sample gene set enrichment (ssGSEA) analyses were employed to investigate the association of risk score with immune status and the tumor microenvironment. Prognostic gene expression levels in AML samples and normal controls were confirmed by qRT-PCR and immunofluorescence. RESULTS: We identified a potential inflammatory response-related signature comprising 11 differentially expressed genes, including ACVR2A, CCL22, EBI3, EDN1, FFAR2, HRH1, ICOSLG, IL-10, INHBA, ITGB3, and LAMP3, and found that AML patients with high expression levels in the high-risk group had poor OS rates. Biological function analyses revealed that prognostic genes mainly participated in inflammation and immunity signaling pathways. Analyses of cancer-infiltrating immunocytes indicated that in high-risk patients, the immune suppressive microenvironment was significantly affected. The expression of the inflammation reaction-associated signature was found to be associated with susceptibility to chemotherapy. There was a significant difference in prognostic gene expression between AML and control tissues. CONCLUSION: A novel inflammatory response-related signature was developed with 11 candidate genes to predict prognosis and immune status in AML patients. AJTR
OBJECTIVE: To determine the prognostic significance of inflammatory response-associated genes in acute myeloid leukemia (AML). METHODS: Transcriptomic profiles and related clinical information of AML patients were acquired from a public database. To establish a multi-gene prognosis signature, we performed least absolute shrinkage and selection operator Cox analysis for the TCGA cohort and evaluated the ICGC cohort for verification. Subsequently, Kaplan-Meier analysis was carried out to compare the overall survival (OS) rates between high- and low-risk groups. Biological function and single-sample gene set enrichment (ssGSEA) analyses were employed to investigate the association of risk score with immune status and the tumor microenvironment. Prognostic gene expression levels in AML samples and normal controls were confirmed by qRT-PCR and immunofluorescence. RESULTS: We identified a potential inflammatory response-related signature comprising 11 differentially expressed genes, including ACVR2A, CCL22, EBI3, EDN1, FFAR2, HRH1, ICOSLG, IL-10, INHBA, ITGB3, and LAMP3, and found that AML patients with high expression levels in the high-risk group had poor OS rates. Biological function analyses revealed that prognostic genes mainly participated in inflammation and immunity signaling pathways. Analyses of cancer-infiltrating immunocytes indicated that in high-risk patients, the immune suppressive microenvironment was significantly affected. The expression of the inflammation reaction-associated signature was found to be associated with susceptibility to chemotherapy. There was a significant difference in prognostic gene expression between AML and control tissues. CONCLUSION: A novel inflammatory response-related signature was developed with 11 candidate genes to predict prognosis and immune status in AML patients. AJTR
Authors: Curdin Conrad; Josh Gregorio; Yi-Hong Wang; Tomoki Ito; Stephan Meller; Shino Hanabuchi; Sonya Anderson; Neely Atkinson; Pedro T Ramirez; Yong-Jun Liu; Ralph Freedman; Michel Gilliet Journal: Cancer Res Date: 2012-07-31 Impact factor: 12.701
Authors: Simon J Dovedi; Viia Valge-Archer; Kyoko Nakamura; Ankur Karmokar; Paul M Farrington; Neil H James; Antonio Ramos-Montoya; Susan J Bickerton; Gareth D Hughes; Timothy M Illidge; Elaine B Cadogan; Barry R Davies Journal: Clin Cancer Res Date: 2021-05-19 Impact factor: 12.531
Authors: A Iellem; M Mariani; R Lang; H Recalde; P Panina-Bordignon; F Sinigaglia; D D'Ambrosio Journal: J Exp Med Date: 2001-09-17 Impact factor: 14.307